{
    "nctId": "NCT02089854",
    "briefTitle": "Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer",
    "officialTitle": "Evaluation of Adjuvant Endocrine Therapy for Operable ER-beta Positive, ER-alpha/PR Negative, Her-2 Negative Breast Cancer Patients",
    "overallStatus": "UNKNOWN",
    "conditions": "Female Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 800,
    "primaryOutcomeMeasure": "disease-free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* The patients signed the written informed consent.\n* The patients present with histologically proven operable invasive breast cancers without distant metastasis.\n* The breast tumor's positive ER/PR rate is \\<1%, and positive ER-beta rate is \u22651% by immuno-histochemistry(IHC).\n* The patients have no history of neoadjuvant hormone therapy.\n* The patients' Karnofsky performance score \u226570%.\n* Female patient who is \u2265 18yrs, and \u2264 80yrs.\n* The patients are non-pregnant, and disposed to practice contraception during the whole trial.\n* The patients underwent neoadjuvant chemotherapy plus surgery or directly modified radical mastectomy or breast-conserving surgery (plus sentinel lymph node biopsy or axillary lymph node dissection) after diagnosis of breast cancer.\n* The patients underwent chemotherapy, radiation therapy after surgery according to the 2013 NCCN guideline.\n* The results of patients' blood tests are as follows:\n\nHb\u226590g/L; WBC\u22654.0\u00d7109/L; Neutrophils\u22651.5\u00d7109/L; Plt\u2265100\u00d7109/L; alanine aminotransferase(ALT) and aspartate aminotransferase (AST) \u2264 2.5 \u00d7 upper limit of normal(ULN); total bilirubin(TBIL) \u2264 1.5\u00d7ULN; Creatinine \u2264 1.25\u00d7ULN.\n\nExclusion Criteria:\n\n* The patients have a previous history of invasive malignant disease (breast cancer at any time, other malignant disorders within the past 10 years excluding squamous or basal-cell carcinoma of the skin or carcinoma in situ of the cervix, adequately cone biopsied).\n* The patients have any severe concomitant disease which will place the patient at unusual risk or confound the results of the trial.\n* The patients have history of neoadjuvant hormone therapy.\n* The patients are undergoing current administration of anti-cancer therapies, or are attending other clinical trials.\n* The patients are pregnant or lactational, or they refuse to practice contraception during the whole trial.\n* The patients are unwilling to stop any hormonal drug including hormone replacement therapy(HRT).\n* The patients can't understand the written informed consent; such as they have dementia.\n* The patients have allergic history or contraindication of toremifene/anastrozole.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}